658 related articles for article (PubMed ID: 32860964)
1. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
Rodríguez-Baño J; Pachón J; Carratalà J; Ryan P; Jarrín I; Yllescas M; Arribas JR; Berenguer J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Clin Microbiol Infect; 2021 Feb; 27(2):244-252. PubMed ID: 32860964
[TBL] [Abstract][Full Text] [Related]
2. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
[TBL] [Abstract][Full Text] [Related]
3. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.
Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S
Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.
Duarte-Millán MA; Mesa-Plaza N; Guerrero-Santillán M; Morales-Ortega A; Bernal-Bello D; Farfán-Sedano AI; García de Viedma-García V; Velázquez-Ríos L; Frutos-Pérez B; De Ancos-Aracil CL; Soria Fernández-Llamazares G; Toledano-Macías M; Cristóbal-Bilbao R; Luquín-Ciuro N; Marrero-Francés J; Piedrabuena-García SI; Satué-Bartolomé JA; Gonzalo-Pascua S; Rivilla-Jiménez M; Carpintero-García L; Ayala-Larrañaga I; García-Bermúdez V; Lara-Montes C; Llerena-Riofrío ÁR; RIvas-Prado L; Walter S; Escriba-Barcena A; San Martín López JV; Ruíz-Giardín JM
J Med Virol; 2022 Apr; 94(4):1540-1549. PubMed ID: 34845754
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
Brosnahan SB; Chen XJC; Chung J; Altshuler D; Islam S; Thomas SV; Winner MD; Greco AA; Divers J; Spiegler P; Sterman DH; Parnia S
Ann Pharmacother; 2022 Mar; 56(3):237-244. PubMed ID: 34180274
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
[TBL] [Abstract][Full Text] [Related]
7. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
8. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Bartoletti M; Marconi L; Scudeller L; Pancaldi L; Tedeschi S; Giannella M; Rinaldi M; Bussini L; Valentini I; Ferravante AF; Potalivo A; Marchionni E; Fornaro G; Pascale R; Pasquini Z; Puoti M; Merli M; Barchiesi F; Volpato F; Rubin A; Saracino A; Tonetti T; Gaibani P; Ranieri VM; Viale P; Cristini F;
Clin Microbiol Infect; 2021 Jan; 27(1):105-111. PubMed ID: 32971254
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.
López-Medrano F; Pérez-Jacoiste Asín MA; Fernández-Ruiz M; Carretero O; Lalueza A; Maestro de la Calle G; Caro JM; de la Calle C; Catalán M; García-García R; Martínez-López J; Origüen J; Ripoll M; San Juan R; Trujillo H; Sevillano Á; Gutiérrez E; de Miguel B; Aguilar F; Gómez C; Silva JT; García-Ruiz de Morales D; Saro-Buendía M; Marrero-Sánchez Á; Chiara-Graciani G; Bueno H; Paz-Artal E; Lumbreras C; Pablos JL; Aguado JM;
Int J Infect Dis; 2021 Apr; 105():487-494. PubMed ID: 33647515
[TBL] [Abstract][Full Text] [Related]
12. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.
Liu Z; Li X; Fan G; Zhou F; Wang Y; Huang L; Yu J; Yang L; Shang L; Xie K; Xu J; Huang Z; Gu X; Li H; Zhang Y; Wang Y; Huang Z; Cao B
Clin Microbiol Infect; 2021 Jan; 27(1):112-117. PubMed ID: 33007478
[TBL] [Abstract][Full Text] [Related]
13. Treatment for COVID-19-a cohort study from Northern Italy.
Guglielmetti L; Aschieri D; Kontsevaya I; Calabrese F; Donisi A; Faggi A; Ferrante P; Fronti E; Gerna L; Leoni MC; Paolillo F; Ratti G; Ruggieri A; Sacchini D; Scotti M; Valdatta C; Stabile M; Taliani G; Codeluppi M
Sci Rep; 2021 Oct; 11(1):20964. PubMed ID: 34697322
[TBL] [Abstract][Full Text] [Related]
14. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
15. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
16. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
Rubio-Rivas M; Mora-Luján JM; Montero A; Aguilar García JA; Méndez Bailón M; Fernández Cruz A; Oriol I; Teigell-Muñoz FJ; Dendariena Borque B; De la Peña Fernández A; Fernández González R; Gil Sánchez R; Fernández Fernández J; Catalán M; Cortés-Rodríguez B; Mella Pérez C; Montero Rivas L; Suárez Fuentetaja R; Ternero Vega JE; Ena J; Martin-Urda Díez-Canseco A; Pérez García C; Varona JF; Casas-Rojo JM; Millán Núñez-Cortés J;
J Gen Intern Med; 2022 Jan; 37(1):168-175. PubMed ID: 34664188
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
Hill JA; Menon MP; Dhanireddy S; Wurfel MM; Green M; Jain R; Chan JD; Huang J; Bethune D; Turtle C; Johnston C; Xie H; Leisenring WM; Nina Kim H; Cheng GS
J Med Virol; 2021 Apr; 93(4):2270-2280. PubMed ID: 33200828
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
Fisher MJ; Marcos Raymundo LA; Monteforte M; Taub EM; Go R
Int J Infect Dis; 2021 Feb; 103():536-539. PubMed ID: 33333252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
